Shield’s Q3 2024 update indicates net revenues of $7.2m from c43,500 prescriptions of ACCRUFeR®, reflecting an average net selling price (NSP) of $167 which includes the impact of the summer buying pattern by wholesalers/pharmacies in June/July. Ex-July, the average Q3 NSP was $192 with a similar level expected to be maintained in Q4. Shield also confirms a $5m extension to its working capital financing facility with Sallyport, the implementation of a 10% cost saving plan to its operating cost b ....
